Analysts predict Eli Lilly's stock price could reach or exceed $1,200 per share. The company's exceptional financial performance and market dominance in weight-loss and diabetes treatments fuel this outlook.
Eli Lilly reported $19.8 billion in revenue for the first quarter of 2026. This marks a 56% increase from the prior year's same period. Blockbuster GLP-1 drugs Mounjaro and Zepbound drove these results. They generated nearly $13 billion in the quarter. The company raised its full-year revenue guidance. It now projects a range of $82 billion to $85 billion.